California-based Rune Labs, a precision neurology software and data platform company, is partnering with BlueRock Therapeutics, a clinical-stage biopharmaceutical company and subsidiary of Bayer AG, to aid in studying Parkinson's disease.
BlueRock will utilize Rune Labs' clinical development platform, StriveStudy, for clinical trial enrollment, real-world evidence data generation and monitoring...
Brain data startup Rune Labs announced Tuesday it received FDA 510(k) clearance to use its StrivePD app to monitor Parkinson's disease patients' symptoms through the Apple Watch.
The StrivePD system uses Apple's Movement Disorder API to track tremors and dyskinesia, or uncontrolled, involuntary body movement. Patients can also use the app to log their medications, side effects and other symptoms...
Oxford Drug Design raises £2.2M to develop AI-based drug discovery programme
Biotechnology firm Oxford Drug Design Limited (ODD) has raised £2.2M in funding from existing investors ACF Investors, o2h Ventures, Meltwind Advisory, several returning angels and new investors and the US-based R42 Group.
The Oxford University spinout has created an artificial intelligence (AI) AI proprietary platform...
Rune Labs, a San Francisco-based brain data startup, closed a $22.8 million Series A funding round led by Eclipse Ventures.
Additional investors in the round include DigiTx Partners and Moment Ventures. As a part of its investment, Eclipse Ventures Partner Justin Butler will join Rune Labs’ board of directors.
WHAT IT DOES
Founded in 2018 to accelerate the development of medicines for...
